Based on the available data, “oncochannels” such as KCa3.1 as well as dysregulated signaling pathways that depend on these channels may be promising candidates in the therapy of various solid tumors including, among others, glioblastoma, endometrial, prostate, breast, hepatocellular, and cervical carcinoma. Here, KCNN4 is linked to glioblastoma.